Sun Pharmaceutical’s Landmark $11.75B Acquisition of Organon: The Biggest Healthcare Deal of 2026
India’s leading pharmaceutical giant, Sun Pharmaceutical Industries, has inked a deal to acquire New Jersey-based women’s health specialist, Organon & Co. The $11.75 billion acquisition marks the largest healthcare deal of 2026.
The all-cash transaction, announced on April 26, 2026, will see Sun Pharma pay $14 per share for Organon. This represents a 24% premium over the company’s closing price and a staggering 100% premium since the beginning of April. The acquisition propels Sun Pharma into the elite league of the top 25 global pharmaceutical companies, boasting combined revenues of $12.4 billion.
Organon, a spin-off from Merck in 2021, has a strong presence in women’s health products, biosimilars, and established medicines across 140 countries. This strategic acquisition will position Sun Pharma as the third leading company globally in women’s health and a top-10 player in biosimilars. It will also significantly reduce its dependence on generic drugs.
Following the announcement, Sun Pharma shares saw a 7% surge. The transaction is set to close in early 2027, subject to regulatory approvals and stockholder consent. J.P. Morgan and Jefferies are serving as financial advisors to Sun Pharma.
Sources: Organon Official | CNBC